Development of a quantitative method for active epidermal growth factor extracted from dissolving microneedle by solid phase extraction and liquid chromatography electrospray ionization mass spectrometry

Suyong Kim, Minjoo Park, Huisuk Yang, Manita Dangol, Shayan F. Lahiji, Inyoung Huh, Miroo Kim, Jaeick Lee, Junghyun Son, Hyungil Jung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Dissolving microneedle (DMN), a transdermal drug delivery in which biological drugs are encapsulated in biodegradable and biocompatible polymers, was fabricated using epidermal growth factor (EGF) as a model drug and hyaluronic acid (HA) as a backbone polymeric matrix. After mixing calibration and DMN samples with insulin, an internal standard, solid phase extraction (SPE) was performed to separate EGF and insulin from HA, and then liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) was conducted for microgram-scale quantitation. The method showed good linearity (R2 = 0.997) within a specified range (1–4 μg). Additionally, the decrease in EGF levels during DMN fabrication was compared using the SPE/LC-ESI-MS and enzyme-linked immunosorbent assay (ELISA), a traditional analytical method. The ELISA method detected an EGF loss of only 3.88 ± 4.67%, whereas SPE/LC-ESI-MS detected a loss of 16.75 ± 4.39%. Qualitative analysis by circular dichroism showed wavelength shift and splitting after DMN fabrication indicating that EGF was denatured during DMN fabrication and cell viability test showed SPE/LC-ESI-MS is more accurate and reliable for detecting the amount of active EGF loaded into the DMN than ELISA.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume131
DOIs
Publication statusPublished - 2016 Nov 30

Fingerprint

Electrospray ionization
Electrospray Ionization Mass Spectrometry
Solid Phase Extraction
Liquid chromatography
Epidermal Growth Factor
Liquid Chromatography
Mass spectrometry
Immunosorbents
Assays
Enzyme-Linked Immunosorbent Assay
Hyaluronic Acid
Fabrication
Enzymes
Pharmaceutical Preparations
Insulin
Dichroism
Circular Dichroism
Drug delivery
Calibration
Cell Survival

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

@article{fb02521534c64a26a56b1b48536cb07e,
title = "Development of a quantitative method for active epidermal growth factor extracted from dissolving microneedle by solid phase extraction and liquid chromatography electrospray ionization mass spectrometry",
abstract = "Dissolving microneedle (DMN), a transdermal drug delivery in which biological drugs are encapsulated in biodegradable and biocompatible polymers, was fabricated using epidermal growth factor (EGF) as a model drug and hyaluronic acid (HA) as a backbone polymeric matrix. After mixing calibration and DMN samples with insulin, an internal standard, solid phase extraction (SPE) was performed to separate EGF and insulin from HA, and then liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) was conducted for microgram-scale quantitation. The method showed good linearity (R2 = 0.997) within a specified range (1–4 μg). Additionally, the decrease in EGF levels during DMN fabrication was compared using the SPE/LC-ESI-MS and enzyme-linked immunosorbent assay (ELISA), a traditional analytical method. The ELISA method detected an EGF loss of only 3.88 ± 4.67{\%}, whereas SPE/LC-ESI-MS detected a loss of 16.75 ± 4.39{\%}. Qualitative analysis by circular dichroism showed wavelength shift and splitting after DMN fabrication indicating that EGF was denatured during DMN fabrication and cell viability test showed SPE/LC-ESI-MS is more accurate and reliable for detecting the amount of active EGF loaded into the DMN than ELISA.",
author = "Suyong Kim and Minjoo Park and Huisuk Yang and Manita Dangol and {F. Lahiji}, Shayan and Inyoung Huh and Miroo Kim and Jaeick Lee and Junghyun Son and Hyungil Jung",
year = "2016",
month = "11",
day = "30",
doi = "10.1016/j.jpba.2016.09.002",
language = "English",
volume = "131",
pages = "297--302",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

Development of a quantitative method for active epidermal growth factor extracted from dissolving microneedle by solid phase extraction and liquid chromatography electrospray ionization mass spectrometry. / Kim, Suyong; Park, Minjoo; Yang, Huisuk; Dangol, Manita; F. Lahiji, Shayan; Huh, Inyoung; Kim, Miroo; Lee, Jaeick; Son, Junghyun; Jung, Hyungil.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 131, 30.11.2016, p. 297-302.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a quantitative method for active epidermal growth factor extracted from dissolving microneedle by solid phase extraction and liquid chromatography electrospray ionization mass spectrometry

AU - Kim, Suyong

AU - Park, Minjoo

AU - Yang, Huisuk

AU - Dangol, Manita

AU - F. Lahiji, Shayan

AU - Huh, Inyoung

AU - Kim, Miroo

AU - Lee, Jaeick

AU - Son, Junghyun

AU - Jung, Hyungil

PY - 2016/11/30

Y1 - 2016/11/30

N2 - Dissolving microneedle (DMN), a transdermal drug delivery in which biological drugs are encapsulated in biodegradable and biocompatible polymers, was fabricated using epidermal growth factor (EGF) as a model drug and hyaluronic acid (HA) as a backbone polymeric matrix. After mixing calibration and DMN samples with insulin, an internal standard, solid phase extraction (SPE) was performed to separate EGF and insulin from HA, and then liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) was conducted for microgram-scale quantitation. The method showed good linearity (R2 = 0.997) within a specified range (1–4 μg). Additionally, the decrease in EGF levels during DMN fabrication was compared using the SPE/LC-ESI-MS and enzyme-linked immunosorbent assay (ELISA), a traditional analytical method. The ELISA method detected an EGF loss of only 3.88 ± 4.67%, whereas SPE/LC-ESI-MS detected a loss of 16.75 ± 4.39%. Qualitative analysis by circular dichroism showed wavelength shift and splitting after DMN fabrication indicating that EGF was denatured during DMN fabrication and cell viability test showed SPE/LC-ESI-MS is more accurate and reliable for detecting the amount of active EGF loaded into the DMN than ELISA.

AB - Dissolving microneedle (DMN), a transdermal drug delivery in which biological drugs are encapsulated in biodegradable and biocompatible polymers, was fabricated using epidermal growth factor (EGF) as a model drug and hyaluronic acid (HA) as a backbone polymeric matrix. After mixing calibration and DMN samples with insulin, an internal standard, solid phase extraction (SPE) was performed to separate EGF and insulin from HA, and then liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) was conducted for microgram-scale quantitation. The method showed good linearity (R2 = 0.997) within a specified range (1–4 μg). Additionally, the decrease in EGF levels during DMN fabrication was compared using the SPE/LC-ESI-MS and enzyme-linked immunosorbent assay (ELISA), a traditional analytical method. The ELISA method detected an EGF loss of only 3.88 ± 4.67%, whereas SPE/LC-ESI-MS detected a loss of 16.75 ± 4.39%. Qualitative analysis by circular dichroism showed wavelength shift and splitting after DMN fabrication indicating that EGF was denatured during DMN fabrication and cell viability test showed SPE/LC-ESI-MS is more accurate and reliable for detecting the amount of active EGF loaded into the DMN than ELISA.

UR - http://www.scopus.com/inward/record.url?scp=84989170902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989170902&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2016.09.002

DO - 10.1016/j.jpba.2016.09.002

M3 - Article

C2 - 27616007

AN - SCOPUS:84989170902

VL - 131

SP - 297

EP - 302

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -